Abstract
Carfilzomib, a second-generation proteasome inhibitor, has been increasingly used in relapsed/refractory multiple myeloma (MM) since its approval by the American food and drug administration (FDA) in the summer of 2012. The drug is active as a single agent and in combination with other antimyeloma agents. As a result of its efficacy and safety in the relapsed/refractory setting, carfilzomib is being evaluated in patients with newly diagnosed MM as well as in high-risk smoldering MM. This review will give a comprehensive summary of the drug, including its mechanism of action, the evaluated doses and schedules as well as a summary of the main clinical trials in the relapsed/refractory and newly diagnosed settings. A focus will be placed upon certain subgroups of interest as well as a description of the toxicity associated with carfilzomib use and a clinical perspective on toxicity management.
Original language | English (US) |
---|---|
Pages (from-to) | 564-577 |
Number of pages | 14 |
Journal | European Journal of Haematology |
Volume | 96 |
Issue number | 6 |
DOIs | |
State | Published - Jun 1 2016 |
Keywords
- Carfilzomib
- Combination regimen
- Induction
- Multiple myeloma
- Proteasome inhibitors
- Relapse
ASJC Scopus subject areas
- Hematology